Welcome to our dedicated page for Jaguar Health SEC filings (Ticker: JAGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Jaguar Health, Inc. (NASDAQ: JAGX) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures, giving investors structured access to its capital markets activity and material agreements. Jaguar is a commercial-stage pharmaceuticals company focused on plant-based prescription medicines for gastrointestinal distress in humans and animals, and its filings provide insight into how it finances and supports these programs.
Recent Form 8-K filings describe a range of transactions, including secured and unsecured promissory notes, royalty interest agreements and amendments, PIPE financings involving Series N Perpetual Preferred Stock and common stock with pre-funded warrants, and privately negotiated exchanges of preferred stock for common shares and pre-funded warrants. Other 8-Ks outline at-the-market offering amendments, conditional approval-related developments for Canalevia-CA1, and note purchase agreements backed by deposit account control arrangements and subsidiary guarantees.
Jaguar’s proxy materials, such as definitive proxy statements on Schedule 14A, detail stockholder proposals to approve share issuances under Nasdaq Listing Rule 5635(d), including common stock issuable upon exchange of Series L, Series M, and Series N preferred stock and upon conversion of certain convertible promissory notes and related warrants. These documents also explain voting rights, voting caps for preferred series, and the structure of special and annual meetings.
On this page, users can review Jaguar’s 10-K and 10-Q reports (when available) for broader business and risk disclosures, while Form 4 and related ownership filings provide visibility into insider equity transactions. Stock Titan enhances these filings with AI-powered summaries that highlight key terms in complex documents, such as interest rates, maturity dates, collateral arrangements, voting provisions, and share issuance conditions. Real-time updates from EDGAR ensure that new Jaguar Health filings, including 8-Ks announcing material events, are quickly accessible with plain-language explanations.
Jaguar Health, Inc. reported an equity compensation award to executive Steven R. King, who serves as Chief of Sustainable Supply, Ethnobotanical Research and Intellectual Property and Secretary. On December 11, 2025, he was granted 11,740 shares of common stock, bringing his directly held common stock to 11,885 shares. These shares reflect restricted stock units granted under the company’s 2014 Stock Incentive Plan and are scheduled to vest on December 11, 2026, with shares delivered on the vesting date.
On the same date, King also received a stock option for 11,740 shares of common stock with an exercise price of $1.44 per share, expiring on December 11, 2035. The option vests in equal monthly installments over 12 months from the grant date, contingent on his continued employment. Both the restricted stock units and options were approved by the board of directors as part of the company’s stock incentive program, and were reported as directly owned.
Jaguar Health, Inc. reported an equity compensation grant to Chief Executive Officer and President Lisa A. Conte, who is also a director. On December 11, 2025, she received 28,592 restricted stock units of common stock at a price of $0, increasing her directly owned common shares to 29,258. Each unit represents one share and will vest on December 11, 2026, with shares delivered on that date.
On the same date, she was granted stock options for 28,592 shares of common stock with an exercise price of $1.44 per share, expiring on December 11, 2035. These options vest ratably on a monthly basis over 12 months from the grant date, contingent on her continued employment, and were issued under the company’s 2014 Stock Incentive Plan.
Jaguar Health, Inc. reported an equity award to officer Jonathan S. Wolin, who serves as Chief of Staff, Chief Compliance Officer and General Counsel. On December 11, 2025, he received 11,740 shares of common stock in the form of restricted stock units at a price of $0, granted under the company’s 2014 Stock Incentive Plan. These restricted stock units each represent one share of voting common stock and are scheduled to vest on December 11, 2026, with shares delivered on the vesting date as provided in the grant notice.
On the same date, he was also granted a stock option for 11,740 shares of common stock with an exercise price of $1.44 per share, expiring on December 11, 2035. The option vests ratably on a monthly basis over 12 months from the grant date, contingent on his continued employment. After these grants, he directly beneficially owned 11,938 shares of common stock and options covering 11,740 shares.
Jaguar Health, through its subsidiary Napo Pharmaceuticals, entered a major U.S. license and supply deal for its Mytesi and Canalevia products with Woodward Specialty, an affiliate of Future Pak. Napo granted the licensee exclusive rights to commercialize these products in the United States and will supply finished product under a separate supply agreement.
In return, Napo receives an upfront payment of $18 million, consisting of $16 million paid on January 12, 2026 and a $2 million holdback contingent on specified conditions by the six‑month anniversary of that date, plus potential milestone payments of up to $17 million tied to defined events. Future Pak provides limited guarantees of the licensee’s milestone and supply payment obligations. Starting after the fifth anniversary of the effective date, if Napo secures U.S. FDA approval for additional Mytesi indications and complies with the agreement, it has a unilateral option to buy back all licensed rights by making a contractually defined payment.
Jaguar Health, Inc. filed an amended current report to correct execution, closing, and report dates related to a recent financing agreement, and to replace prior exhibits with corrected versions. On January 6, 2026, the company entered into securities purchase agreements with two accredited investors and issued $350,000 aggregate principal amount of unsecured promissory notes, bearing interest at 6% per annum and maturing one month after issuance. The company may prepay the notes without penalty and plans to use the proceeds for working capital and general corporate purposes. As an inducement, the investors received warrants to purchase up to 350,000 shares of common stock at an initial exercise price of $1.00 per share, exercisable immediately and expiring after up to five years or upon certain corporate events. The securities were sold in a private placement relying on exemptions under Section 4(a)(2) and Rule 506 of Regulation D.
Jaguar Health, Inc. filed an amended current report to correct dates in a prior disclosure and to fully restate the terms of a recent financing. On January 6, 2026, the company entered into securities purchase agreements with two accredited investors and issued $350,000 aggregate principal amount of unsecured promissory notes, with proceeds to be used for working capital and other general corporate purposes. The notes bear 6% annual interest, mature one month after issuance, and may be prepaid without penalty. As an inducement, the investors also received warrants to purchase up to 350,000 shares of common stock at an initial exercise price of $1.00 per share, exercisable immediately and expiring upon the earliest of five years from issuance, a fundamental transaction, or a liquidation event.
Jaguar Health, Inc. entered into securities purchase agreements with two accredited investors, issuing $350,000 aggregate principal amount of unsecured promissory notes to raise funds for working capital and other general corporate purposes. The notes bear 6% annual interest and mature one month after issuance, and may be prepaid at any time without penalty.
As an inducement, the investors received warrants to purchase up to 350,000 shares of common stock at an initial exercise price of $1.00 per share, exercisable immediately and expiring on the earlier of five years from issuance, a fundamental transaction, or a liquidation event. The securities were issued in a private offering relying on exemptions under Section 4(a)(2) and Rule 506 of Regulation D.
Jaguar Health Chief Scientific Officer Pravin Chaturvedi reported new equity awards in the company’s stock. On December 11, 2025, he received 11,740 restricted stock units, each representing a right to one share of Jaguar Health voting common stock. These restricted stock units vest on December 11, 2026, when the underlying shares are scheduled to be delivered.
On the same date, he was also granted a stock option covering 11,740 shares of common stock at an exercise price of $1.44 per share, expiring on December 11, 2035. The option vests ratably on a monthly basis over 12 months from the grant date, as long as he remains employed, and both awards were granted under Jaguar Health’s 2014 Stock Incentive Plan. Following the grant, he beneficially owned 11,938 shares of common stock directly, plus the 11,740 stock options. The filing also notes a 25-for-1 reverse stock split of Jaguar’s voting common stock effective March 24, 2025.
Jaguar Health director James J. Bochnowski reported new equity awards. On December 11, 2025, he received 6,363 restricted stock units and a stock option for 6,363 shares of common stock, granted under the company’s 2014 Stock Incentive Plan.
Each restricted stock unit represents one share of voting common stock and will vest on December 11, 2026, with shares delivered on that date. The stock option has an exercise price of $1.44 per share, vests ratably on a monthly basis over 12 months from the grant date while he continues serving on the board, and expires on December 11, 2035.
Following the grant, Bochnowski beneficially owned 6,415 shares of Jaguar Health common stock directly.
Jaguar Health director Jonathan B. Siegel reported receiving new equity awards under the company’s 2014 Stock Incentive Plan. The filing shows 7,377 restricted stock units and a stock option covering 7,377 shares of common stock, both granted on 12/11/2025 at no cost for the awards themselves, with the option carrying a $1.44 exercise price and expiring on 12/11/2035.
The restricted stock units are scheduled to vest on 12/11/2026, while the options vest ratably on a monthly basis over 12 months from the grant date, contingent on his continued board service at Jaguar Health and its subsidiary Napo Therapeutics, S.p.A. Following these grants, he directly beneficially owned 7,423 shares of Jaguar Health common stock.